NVO
Novo Nordisk A/S
NVO has slightly lower modeled downside risk, despite its lower overall score.
STVN
Stevanato Group S.p.A.
STVN has the edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Healthy |
STVN's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over STVN in the historical PE scenario, which offers more potential upside but is not a forecast.
STVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 27x | $14.36 | — |
| Cheap | 31x | $16.55 | +15% |
| Fair | 39x | $20.56 | +43% |
| Expensive | 49x | $25.80 | +80% |
Historical ranges are pointers, not guarantees.
STVN's PE is 27x, but its earnings don't support one, so it isn't a reliable read right now.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect STVN's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STVN on earnings, with more consistent year-over-year improvement.
STVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.53 | -5.4% |
| Q1 2026 | $0.57 | +9.6% |
| Q4 2025 | $0.57 | +16% |
| Q3 2025 | $0.58 | +23% |
| Q2 2025 | $0.56 | +7.7% |
| Q1 2025 | $0.52 | -10% |
| Q4 2024 | $0.49 | -21% |
| Q3 2024 | $0.47 | -24% |
STVN earned $0.53 per share over the past year, down 5.4% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STVN on profitability, with a higher operating margin.
STVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $335.5M | +7.8% |
| Q1 2026 | $303.9M | +6.6% |
| Q4 2025 | $381.3M | +3.8% |
| Q3 2025 | $336.8M | +9.1% |
| Q2 2025 | $311.1M | +7.9% |
| Q1 2025 | $285.1M | +8.7% |
| Q4 2024 | $367.3M | +3.1% |
| Q3 2024 | $308.7M | +2.4% |
STVN's revenue has grown year over year for nine quarters in a row: $335M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -1.8 points |
| Q1 2026 | 14% | +0.7 points |
| Q4 2025 | 19% | -1 points |
| Q3 2025 | 17% | +2.6 points |
| Q2 2025 | 15% | +4 points |
| Q1 2025 | 14% | +2.8 points |
| Q4 2024 | 20% | +0.3 points |
| Q3 2024 | 15% | -4.1 points |
STVN's operating margin was 13% last quarter, down 1.8 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over STVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
STVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$37.6M | -$20.6M |
| Q1 2026 | $5.3M | -83% |
| Q4 2025 | $5.2M | +$55.4M |
| Q3 2025 | -$1.3M | +$121.2M |
| Q2 2025 | -$17.1M | +$34.6M |
| Q1 2025 | $31.2M | +$65.7M |
| Q4 2024 | -$50.3M | +$35.2M |
| Q3 2024 | -$122.5M | +$166.1M |
STVN has burned cash in most quarters: −$28M over the past year, against −$159M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -21.1K shares |
| 1 year | 0% | +77K shares |
| 3 years | +2.9% | +7.6M shares |
| 5 years | -9.1% | -27.4M shares |
| Available history | -7.4% | -21.8M shares |
STVN has 273M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
STVN hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over STVN on leverage, with a lower net debt burden relative to earnings.
STVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.0x | Healthy |
| Q1 2025 | 1.0x | Healthy |
| Q4 2024 | 1.1x | Healthy |
| Q3 2024 | 1.0x | Healthy |
STVN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.2 | Neutral |
| Stochastic | 17.5 | Oversold |
STVN's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over STVN on valuation relative to its sector.
STVN PE vs Healthcare Sector
| Metric | STVN | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 4.2% above |
| PE % | 6 | 38 | 32 pts below |
STVN is trading at 27x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over STVN on trend strength, trading above more of its moving averages.
STVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.3 | 22% below |
| 20 week MA | $19.6 | 27% below |
| 50 week MA | $18.2 | 21% below |
| 100 week MA | $20.7 | 30% below |
| 200 week MA | $23.1 | 38% below |
STVN is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over STVN on returns for 2026, with the stronger performance.
STVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $19.7 | $23.3 | +19% |
| 2022 | $23.3 | $17.9 | -23% |
| 2023 | $17.9 | $27.3 | +53% |
| 2024 | $27.3 | $21.6 | -21% |
| 2025 | $21.6 | $20.7 | -4.2% |
| 2026 YTD | $20.7 | $14.4 | -31% |
STVN has finished lower in three of the last five years. It's down 31% so far in 2026.